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OBJECTIVES: Severe acute respiratory syndrome coronavirus-2 affects 
adults disproportionately more than children. A small proportion of children 
with severe acute respiratory syndrome coronavirus-2 required admission 
to a PICU. We describe the nationwide U.K. PICU experience of severe 
acute respiratory syndrome coronavirus-2 infection during the first wave of 
the pandemic and compare this with the critical care course of the 2019 
influenza cohort.
DESIGN: Prospective nationwide cohort study of characteristics of se-
vere acute respiratory syndrome coronavirus-2–positive children. Data col-
lection utilized routine Pediatric Intensive Care Audit Network and severe 
acute respiratory syndrome coronavirus-2–specific data.
SETTING: All U.K. PICUs.
PATIENTS: Children less than 18 years old, admitted to U.K. PICUs be-
tween March 14, 2020, and June 13, 2020, and a positive severe acute 
respiratory syndrome coronavirus-2 polymerase chain reaction. Children 
admitted to U.K. PICUs in 2019 with influenza provided comparison.
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: We identified 76 PICU 
admissions among 73 children with a positive severe acute respiratory syn-
drome coronavirus-2 polymerase chain reaction test. Prevalence of PICU 
admissions per million was 5.2 for children versus 260 for adults. Ten chil-
dren (14%) were identified on routine screening. Seventeen children (23%) 
had pediatric inflammatory multisystem syndrome temporally associated 
with severe acute respiratory syndrome coronavirus-2. Seventeen (23%) 
had coinfections. Invasive ventilation was required in seven of 17 children 
(41%) with pediatric inflammatory multisystem syndrome temporally asso-
ciated with severe acute respiratory syndrome coronavirus-2 versus 38 of 
56 other severe acute respiratory syndrome coronavirus-2 positive children 
(68%), with 77% requiring vasoactive support versus 43%, respectively. 
Seven children (10%) died. In comparison with influenza children, severe 
acute respiratory syndrome coronavirus-2 children were older (median [in-
terquartile range]: 10 [1–13] vs 3 yr [1–8 yr]), more often Black or Asian 
(52% v 18%), higher weight z score (0.29 [–0.80 to 1.62] vs –0.41 [–1.37 
to 0.63]), and higher deprivation index (3.3 [–1 to 6.3] vs 1.2 [–1.8 to 4.4]). 
Comorbidities, frequency of organ supports, and length of stay were similar.
CONCLUSIONS: This nationwide study confirms that PICU admissions 
with severe acute respiratory syndrome coronavirus-2 infections were 
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infrequent. We have reported similarities and differ-
ences in sociodemographic characteristics, organ 
support interventions, and outcomes of children af-
fected by severe acute respiratory syndrome coro-
navirus-2 compared with influenza.
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Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, the cause of corona-virus disease (COVID-19), appears to be infre-
quent and less severe in children than in adults(1–4). 
Despite the apparent lower risk, some children with 
SARS-CoV-2 infection have required admission to 
PICUs with associated morbidity and mortality(5–8). 
SARS-CoV-2 infection has also been implicated in a 
multisystem inflammatory illness in children, com-
monly referred to as either pediatric inflammatory 
multisystem syndrome temporally associated with 
SARS-CoV-2 (PIMS-TS) or multisystem inflamma-
tory syndrome in children (MIS-C) (9, 10). To date, 
however, there have been few multicenter publica-
tions describing children severely affected by SARS-
CoV-2, and none that represent a whole national 
population.
The aim of this study was to describe the clinical 
characteristics, management, and outcomes for chil-
dren with confirmed SARS-CoV-2 infection prior to 
or during admission to a PICU in the United Kingdom 
during the first wave of the pandemic, using the 
Pediatric Intensive Care Audit Network (PICANet) na-
tional dataset. Influenza infections are associated with 
significant morbidity and mortality in children of all 
ages. As another respiratory infection with varying se-
verity of illness with potential systemic complications, 
influenza may have several similarities with COVID-
19, including hospitalization rates (11). However, there 
is no literature comparing the critical care course of 
the two illnesses in children. The study compares the 
SARS-CoV-2 cohort with a historical cohort of chil-
dren admitted to PICU with influenza. Additionally, 
demographic and clinical characteristics for SARS-
CoV-2–positive children with a clinical phenotype of 
PIMS-TS are compared with those who did not have 
PIMS-TS. This information will inform the ongoing 
management of these children and provide guidance 
for health professionals and families.
METHODS
Inclusion Criteria
This nationwide prospective observational study in-
cluded children less than 18 years old who were admit-
ted to one of the 24 U.K. PICUs and belonged to either 
1) the SARS-CoV-2 cohort: a positive SARS-CoV-2 
reverse transcriptase polymerase chain reaction 
(RT-PCR) test any time during or immediately prior to 
the admission episode during the 3-month period be-
tween March 14, 2020 and June 13, 2020 or 2) the influ-
enza cohort: a primary diagnosis of influenza admitted 
to a U.K. PICU between January 1, and December 31, 
2019. The SARS-CoV-2 cohort included any child with 
a positive RT-PCR test regardless of indication for test-
ing, symptomatology, or presentation such as asymp-
tomatic, respiratory failure, or PIMS-TS/MIS-C.
Data Collection
PICANet collects, analyses, and reports on informa-
tion related to all admissions from all U.K. PICUs (12). 
PICANet has a validated online data entry system, 
and data quality is audited to ensure highest quality 
data. The core PICANet dataset includes information 
related to patient demographics, diagnoses, interven-
tions included in the pediatric critical care minimum 
dataset, and outcome at discharge from PICU, as well 
as severity of illness variables for calculation of the 
Pediatric Index of Mortality (PIM) 3 score (13).
Data collection was expanded during the SARS-
CoV-2 pandemic to include additional information 
concerning all children who tested positive for SARS-
CoV-2 either prior to or during the PICU admission 
(Supplemental Digital Content 2, http://links.lww.
com/CCX/A533 and Supplemental Digital Content 
3, http://links.lww.com/CCX/A534). This included 
the following: SARS-CoV-2 status at admission, up to 
three rounds of testing including date and time of test-
ing, reason for testing (suspected infection or routine 
testing), types of sample taken, results of each test, lab-
oratory markers at admission, coinfections, symptoms, 
and medications. An admission episode was defined 
as any continuous period of intensive care, including 
direct transfers between PICUs. Similarly, children 
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readmitted to a PICU within 48 hours of index dis-
charge were considered as having one continuous 
admission event. Townsend deprivation index scores 
were allocated to children by postcode of residence 
(14). Comorbidities were reviewed for all children 
and grouped into major diagnostic categories. SARS-
CoV-2 positive children were categorized by PICU cli-
nicians as to whether they presented with PIMS-TS or 
not. The SARS-CoV-2 specific dataset was set up prior 
to publication of case-definitions for MIS-C published 
by either the U.S. Centers for Disease Control and 
Prevention or the World Health Organization (15, 16).
Data were validated with all PICUs to ensure 
100% case-ascertainment of all SARS-CoV-2 positive 
patients in the United Kingdom. Any missing data 
items were requested from units to ensure complete-
ness of the data.
Statistical Analysis
Descriptive data were reported as numbers and per-
centages for categorical variables and medians with 
interquartile ranges (IQRs) and mean and sds for con-
tinuous variables. z scores of weight-for-age were cal-
culated to compare the weight of a child with the mean 
weight for a child of the same sex and age using the 
U.K. World Health Organization Growth References, 
accounting for preterm birth where required(17, 18). 
Estimates and 95% CIs for the difference between the 
SARS-CoV-2 and influenza cohorts were obtained 
using t tests for continuous data and two-sample test 
of proportions for discrete variables. SARS-CoV-2 
incidence rates were calculated per 1,000,000 popu-
lation using 2019 midyear population estimates from 
the Office for National Statistics (19). Comparable 
rate of ICU admission for adults was calculated using 
the intensive care national audit and research centre 
case-mix program COVID-19 report dated 12 June 
2020 and midyear population estimates for United 
Kingdom, Wales, and Northern Ireland from the same 
Office for National Statistics report (20). All data were 
analyzed using STATA 16.0 (College Station, TX).
Ethics and Research Governance Approvals
Processing of personally identifiable data for the pur-
poses of service evaluation, audit, and research was 
approved by the Patient Information Advisory Group 
(now the Health Research Authority Confidentiality 
Advisory Group) in 2002 under Section 60 of the 
Health and Social Care Act (subsequently Section 
251 of the National Health Service Act 2006) (refer-
ence: PIAG 4-07(c) 2002). This was amended and 
approved specifically to collect additional data relating 
to COVID-19 for confirmed and suspected cases.
RESULTS
During the study period, 73 children with a positive 
SARS-CoV-2 polymerase chain reaction (PCR) had 76 
PICU admission episodes. Sixty nine children (95%) 
were admitted to a PICU in United Kingdom. During 
the same period in United Kingdom, 1,008 chil-
dren were admitted to hospital with a positive SARS-
CoV-2 PCR, with PICU admission rate of 6.85% (21). 
Eighteen of the 24 U.K. PICUs had at least one child 
admitted with SARS-CoV-2. The population incidence 
of children with SARS-CoV-2 requiring PICU was 5.2 
per million U.K. children 0–17 years old during the 
study period, compared with 260 per million adults 
requiring intensive care admission in a comparable 
time period.
Figure 1 shows weekly numbers of newly confirmed 
SARS-CoV-2 infections and associated cumulative 
totals among children admitted to PICU during the 
study period. The peak was in week 17 (20–26 April 
2020) with 10 children testing SARS-CoV-2 posi-
tive. Over half of these children (n = 39; 53%) were 
admitted to PICUs in London with a further two fifths 
(n = 30; 41%) admitted to PICUs in the rest of United 
Kingdom, and very few children admitted to PICUs in 
the devolved U.K. nations (n = 4; 6%).
Characteristics of SARS-CoV-2–Positive 
Children and Comparison With Influenza Cohort
The characteristics of the SARS-CoV-2–positive chil-
dren admitted to PICUs during the study period 
are presented in Supplementary Digital Content 1 
(http://links.lww.com/CCX/A532) and are compared 
with the 2019 cohort of 243 children admitted to PICU 
with influenza.
In comparison with influenza children, SARS-
CoV-2 children were older (median [IQR]: 10 [1–13] 
vs 3 yr [1–8 yr]). Children under 6 years comprised 
only one third of the SARS-CoV-2 cohort (33%) com-
pared with almost two thirds of the influenza cohort 
(63%). The two cohorts were similar in terms of sex, 
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proportion of unplanned admissions, and PIM3 pre-
dicted mortality risk. Children in PICU with SARS-
CoV-2 were from more deprived areas than the 
influenza cohort (mean [sd] of Townsend index of 
deprivation: 2.7 [4.05] vs 1.5 [3.75]; mean difference: 
1.21 [0.20–2.22]). In addition, there was a suggestion 
of higher proportions of children of Black and Asian 
ethnicity (n = 38; 52%) in the SARS-CoV-2 group 
compared with the influenza (n = 43; 18%) cohort, 
although one fifth of the influenza cohort had miss-
ing ethnicity data. The proportion of children with 
underlying comorbidities appeared similar between 
children with SARS-CoV-2 (31; 43%) and influenza 
(121; 50%). The most common comorbidity for both 
groups of children were similar, with neurologic/
developmental (SARS-CoV-2: 25%; influenza: 24%) 
and prematurity (SARS-CoV-2: 11%; influenza: 
12%) being the most common. A higher proportion 
of children with chronic pulmonary diseases were 
observed in the influenza cohort compared with the 
SARS-CoV-2 cohort. However, the numbers of chil-
dren affected in either group were small. Only eight 
children (11%) with SARS-CoV-2 infection met the 
Public Health England (PHE) criteria for the ex-
tremely vulnerable category requiring shielding 
(22). Differences in distribution of weight z scores 
suggested that the SARS-CoV-2 cohort were heavier 
than the influenza cohort (0.29 [–0.80 to 1.62] vs 
–0.41 [–1.37 to 0.63]). Again, there were high levels 
of missing data in the influenza cohort.
SARS-CoV-2 Symptoms and RT-PCR Tests
Details of the symptoms and testing for the SARS-
CoV-2 cohort are summarized in Supplemental Digital 
Content 2 (http://links.lww.com/CCX/A533). Of the 
common symptoms, 63% of the SARS-CoV-2 cohort 
reported fever (> 37.8°C), 31·5% cough, and none were 
reported to have anosmia. Other commonly reported 
symptoms were abdominal pain (26%), diarrhea 
(25%), rash (21%), and shock (21%). Nine children 
(12%) reported no symptoms.
A positive SARS-CoV-2 result was most commonly 
obtained between 24 hours prior to (n = 17) and 48 hours 
post PICU admission (n = 34). Most children were tested 
for SARS-CoV-2 due to a suspected infection (n = 58; 
79%). However, 10 (14%) were detected during routine 
screening. Details on SARS-CoV-2 testing were unavail-
able for five children; 176 test results from 68 children 
were available for analysis. A range of samples were tested 
including nasopharyngeal aspirate (n = 109; 56% posi-
tive), throat swab (n = 68; 59% positive), endotracheal 
Figure 1. New and cumulative confirmed cases of coronavirus disease 2019 in children treated in PICU in the United Kingdom, by date 
of first laboratory confirmation. Please note information on one children excluded from this graph as date first confirmed positive not 
known. SARS-CoV-2 = severe acute respiratory syndrome coronavirus-2.
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secretions (n = 26; 42% positive), and bronchoalveolar 
lavage (n = 17; 41% positive). Testing types were not mu-
tually exclusive between testing episodes, and a child 
may have had more than one type of test in a testing ses-
sion; however, the majority of children had one single 
test reported to PICANet (n = 53; 78%).
Seventeen children (23%) had other coinfections re-
corded (Supplemental Digital Content 2, http://links.
lww.com/CCX/A533). This included other viral infec-
tions in 13 children, bacterial in seven children, and 
fungal in four children, with multiple infection types 
reported in some (n = 5; 7%).
Management and Outcomes for SARS-CoV-
2–Positive Children and Comparison With 
Influenza Cohort
A range of interventions were reported in SARS-CoV-
2–positive children (Supplemental Digital Content 3, 
http://links.lww.com/CCX/A534); although given 
their comorbidities, it is not possible to attribute the 
interventions to SARS-CoV-2 given multiple co-
morbid conditions, alternative diagnoses, and coin-
fections. Antiviral medications were only reported in 
11 children (15%) in the SARS-CoV-2 cohort, with 
remdesivir (n = 8/11; 73%) being the most common. 
Twenty-two children (30%) received immunomod-
ulatory/anti-inflammatory medications including 
IV immunoglobulin (n = 14; 19%), azithromycin 
(n = 14; 19%), and dexamethasone (n = 6; 8%). Of 
note, 54 children (74%) received antibiotics during 
their PICU stay, but only five children (6%) had a con-
firmed bacterial coinfection.
A lower proportion of children with SARS-CoV-2 
(n = 45; 62%) received invasive ventilatory sup-
port compared with 75% of children with influenza. 
However, a higher proportion of children required 
vasoactive interventions in the SARS-CoV-2 cohort 
(51%) compared with the influenza cohort (35%). 
Some of these differences may, however, be related to 
the subgroup of children with a PIMS-TS phenotype 
(Supplemental Digital Content 3, http://links.lww.
com/CCX/A534). The non–PIMS-TS subgroup of the 
SARS-CoV-2 cohort did have a comparable propor-
tion of children requiring invasive mechanical ventila-
tion (68%) and vasoactive support (43%) relative to the 
influenza cohort. Very small numbers of children in 
both the SARS-CoV-2 and influenza cohorts received 
high frequency oscillation, inhaled nitric oxide, renal 
replacement therapy, and extracorporeal membrane 
oxygenation. The duration of respiratory, vasoactive 
supports, as well as PICU length of stay, was similar 
between the two groups.
Seven children in the SARS-CoV-2 cohort died while 
on PICU, although two deaths occurred more than 28 
days after the first recorded positive SARS-CoV-2 test. 
Two of the seven deaths occurred in children admitted 
to PICU for other unrelated critical illness, with SARS-
CoV-2 infection only identified on screening during 
their PICU stay. Their deaths may have been unrelated 
to COVID-19 illness. All other deaths potentially asso-
ciated with COVID-19 illness occurred in children 12 
years old or older. In addition, four of the seven chil-
dren had other recorded coinfections. Five of the seven 
children, including three of the five with potentially 
COVID-19 associated deaths, had other significant 
comorbidities or other significant noninfective diag-
noses. All seven children received invasive ventilation 
(median length of ventilation = 8 d [3–35 d]), and four 
children also received vasoactive support prior to death.
Characteristics of Children With PIMS-TS and 
Positive SARS-CoV-2 PCR
Supplemental Digital Content 3 (http://links.lww.com/
CCX/A534) compares the characteristics of the SARS-
CoV-2 positive children presenting with PIMS-TS 
phenotype (n = 17; 23%) compared with the rest of 
the cohort (n = 56; 77%). In comparison with non 
PIMS-TS children, the PIMS-TS subgroup of chil-
dren were broadly similar in terms of their ethnicity, 
sex, but more likely to be admitted to a London PICU, 
older age-group, heavier, and from a less deprived 
area. The majority of the PIMS-TS cohort had no un-
derlying comorbidities (n = 12; 71%) compared with 
others (n = 25; 45%). The PIMS-TS subgroup needed 
respiratory support less frequently (59% vs 71%) but 
required vasoactive support more frequently (77% vs 
43%) than the children without PIMS-TS. Similarly, 
children with PIMS-TS were more likely to receive 
IV immunoglobulin, whereas small numbers in each 
group were treated with dexamethasone. There was 
only one death reported in the PIMS-TS subgroup.
DISCUSSION
Using the PICANet dataset, we have described, at 
a population level, the low incidence of need for an 
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intensive care admission in children (5.2 per mil-
lion children) compared with adults (260 per million 
adults). We have also shown that only a small pro-
portion of children hospitalized with SARS-CoV-2 
required PICU (6.85% in United Kingdom). PICU 
admissions were highest in London with noticeable 
and obvious geographical variation across the differ-
ent U.K. regions. We showed clear differences in age 
range as well as other demographic characteristics 
known to be associated with increased severity of risk 
of SARS-CoV-2: weight z scores, ethnicity, and dep-
rivation indices, as well as the requirement for organ 
support between SARS-CoV-2 and influenza (2, 5). 
Importantly, a small but significant proportion of chil-
dren were identified to have SARS-CoV-2 infection on 
routine screening of asymptomatic patients admitted 
to PICU for other reasons. This suggests that routine 
screening may need to be implemented regularly, es-
pecially as some children tested positive more than 1 
week after admission, indicating possible nosocomial 
infection. Coinfections were recorded in 15% of SARS-
CoV-2 cases. We also note that in the SARS-CoV-2 co-
hort, coinfection with other pathogens was relatively 
low and that although many children were treated with 
antibiotics, few had bacterial infections detected. Over 
90% of children were discharged alive after a relatively 
short PICU length of stay, regardless of presentation 
with a respiratory or a PIMS-TS phenotype despite a 
high proportion of children admitted with significant 
comorbidities and other primary diagnoses. Two of the 
deaths were also reported greater than 4 weeks after 
diagnosis of SARS-CoV-2 infection. Of note, the U.K. 
government reports only those deaths within 4 weeks 
of a diagnosis of SARS-CoV-2 infection as COVID-19 
associated (23).
The peak in PICU admissions occurred in the week 
commencing April 1, some weeks after the peak in 
adult ICU admissions (24), possibly related to the in-
crease in PICU admissions of patients with PIMS-TS 
(9). This report is limited to the subgroup of PIMS-TS 
who were SARS-CoV-2 PCR positive. Given the far 
higher numbers of patients with PIMS-TS who were 
SARS-CoV-2 PCR negative (9, 25), the population in-
cidence of PICU admission, as well as the geographical 
and temporal distribution, may be slightly different 
when all patients with PIMS-TS are considered. It is 
unclear whether there are differences between the 
PCR-positive and PCR-negative PIMS-TS children 
either in etiopathogenesis or in clinical presentation. 
Among the PIM-TS patients in our cohort, we noted 
that 11 of 17 (65%) received IV immunoglobulin as 
part of their treatment, in line with the latest U.K. 
Delphi recommendations (26). We have shown a sig-
nificantly higher incidence of SARS-CoV-2 infection 
among patients of Black and Asian ethnicity (52%), 
perhaps even more so than children with all levels of se-
verity of SARS-CoV-2 infection (22%) reported by the 
International Severe Acute Respiratory and Emerging 
Infection Consortium study (4), and in adults requir-
ing ICU admission (25%) for COVID-19 in the United 
Kingdom in the same time period (27). In keeping 
with other reports from U.K. adult ICUs (27), children 
from areas of higher deprivation were overrepresented 
in this cohort when compared with other respiratory 
viral illness such as influenza. However, in part, these 
effects may also reflect the particular geography of in-
fection and childhood population, with London much 
more severely affected than other parts of the United 
Kingdom, which are less deprived and less ethnically 
diverse (28). Association between ethnicity and out-
comes has been previously reported by PICANet with 
a risk-adjusted odds ratio for mortality for south Asian 
children admitted to PICU of 1.36 overall, rising to 2.4 
in the least deprived fifth of the population (29). Exact 
reasons for higher risk of severe infection in the Black 
and Asian ethnicities are unclear.
Compared with the influenza cohort, SARS-CoV-2 
appeared to have a lower proportion of children with 
chronic pulmonary diseases, consistent with the only 
other study comparing the two infections in children 
(11). Children with chronic pulmonary diseases were 
considered to be at high-risk of severe COVID-19, as 
were children with significant immunodeficiency, ma-
lignancy, and other rare diseases. This group of chil-
dren and adults was provided with “shielding” guidance 
from PHE (22). Although it is encouraging that there 
was a low requirement of PICU admission overall, and 
no significant overrepresentation in any of these risk 
groups, it remains unclear whether this was a result 
of the “shielding” guidance. Coinfection with other 
viral pathogens in this study was uncommon, which 
has implications for isolation practices and personal 
protective equipment policies. However, since the re-
ported period of the pandemic occurred in spring, 
lower rates of viral transmission might be expected. 
Rates of coinfections with other respiratory viruses 
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may be substantially higher in the winter period. Of 
note, information about the site or significance of the 
coinfection was unavailable and screening practices to 
detect coinfection may have varied between sites.
In a study of critically ill children with SARS-CoV-2 
from 183 North American PICUs, 530 PICU admis-
sions were reported, of whom 401 were children less 
than 18 years old (6). Similar to our report, they also 
observed relative sparing of infants and young chil-
dren. The median age of SARS-CoV-2 positive children 
admitted to PICU of 10 years in this study was also 
consistent with other North American studies (5, 30). 
Likewise, the proportion of patients with preexisting 
comorbidities in this study was 43%, well within the 
wide range of 24–83% reported in different studies 
of children admitted to PICU (5–8, 30). The propor-
tion of children requiring invasive mechanical ventila-
tion (62%) was significantly higher than that reported 
in other PICU-based studies, ranging from 28% to 
47% (5, 6, 8, 30). Direct comparisons are often diffi-
cult, given different PICU admission criteria, different 
thresholds for intubation between different centers and 
countries, the lack of comparable risk-stratification 
scores such as PIM3, and differences in the proportion 
of patients with PIMS-TS phenotype. It might suggest 
a lower threshold to intubate children in the United 
Kingdom, given the hypothetical concerns of high-
flow nasal cannula oxygen and noninvasive ventilation 
being aerosol generating. However, given the duration 
of respiratory support and PICU length of stay being 
comparable not only to children with influenza in the 
same U.K. PICUs but also with other published SARS-
CoV-2 PICU reports (5, 6, 8), this seems unlikely.
The major strength of this study is that we were able 
to report population-level incidence of PICU admissions 
with 100% case-ascertainment for the United Kingdom 
using PICANet, a well-established and high-quality data-
base (12). This study was prioritized as an urgent public 
health study in the United Kingdom, which ensured 
rapid engagement by all PICUs, despite difficulties asso-
ciated with restrictions associated with the COVID-19 
pandemic. In addition, we were able to describe charac-
teristics of SARS-CoV-2 infection in comparison with 
influenza admissions in children as well as the specific 
characteristics of the PIMS-TS subgroup of patients.
Despite the high-quality dataset, we were unable to 
ascertain the significance of the role SARS-CoV-2 infec-
tion played in either the PICU course or the outcomes 
of these children. It is possible that at least in some 
instances, SARS-CoV-2 infection may have had a rel-
atively minor role, given that 14% were identified on 
routine screening, and 43% had significant preexisting 
comorbidities. Missing ethnicity data in the influenza 
cohort meant that we are uncertain about the increased 
susceptibility of serious SARS-CoV-2 infection in chil-
dren of Black and Asian ethnic groups. We did not in-
dependently confirm the case-definitions of patients 
reported to have PIMS-TS within the dataset but relied 
on individual clinicians to do so. Children with PIMS-TS 
who tested PCR negative were not included in this re-
port. Our customized dataset was limited to two other 
tests in addition to the first positive SARS-CoV-2 test. 
Some patients may have had more tests than reported in 
this study. The criteria for testing patients is likely to have 
differed between units, as well as with time within the 
same units due to increased access to testing in the latter 
half of the study period. A very small number of 16–17 
years olds may have been admitted to adult ICUs rather 
than PICUs, and therefore, the population incidence 
rates may be a slight underestimate. This study is limited 
to information collected during the first wave of the pan-
demic in the United Kingdom, before the emergence of 
variant strains with potentially different characteristics.
Using the first nationwide PICU dataset, we con-
firm the very low incidence of serious SARS-CoV-2 
infection in children in the United Kingdom. We have 
characterized the demographic factors, comorbidities, 
PICU interventions and have described the differ-
ences between this group and those admitted to PICU 
with influenza. We have also identified the detection 
of SARS-CoV-2 in critically ill children, in terms of 
testing time and type, plus the risk of coinfection. It 
is anticipated that this information is helpful for pla-
nning service provision, targeted public health meas-
ures, provide information of clinicians at the bedside 
to manage, and counsel families of critically ill chil-
dren with SARS-CoV-2 infection.
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